Succinylsulfathiazole

Synonyms: 琥珀酰磺胺噻唑; Succinylsulphathiazole
Succinylsulfathiazole(Succinylsulphathiazole)是一种具有口服活性的长效磺胺类抗生素,具有肠道局部特异性抗菌活性,可抑制细菌叶酸合成、降低大肠菌群数量、抑制肠道细菌生长与维生素生物合成并消耗肠道产叶酸细菌,还可调控肝脏 mTOR 信号通路、减少盲肠发酵、降低肝脏叶酸水平与总叶酸排泄量、提高氮排泄量并降低部分膳食纤维的发酵性,并能在大鼠和 C57BL/6 小鼠中诱导叶酸缺乏,引发生物素和叶酸相关的营养缺乏症状。
产品编号: MS-P42973 纯度: 99.22% CAS No.: 116-43-8 分子式: C13H13N3O5S2 分子量: 355.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
询价
50g
询价
询价

产品描述

Succinylsulfathiazole(Succinylsulphathiazole)是一种具有口服活性的长效磺胺类抗生素,具有肠道局部特异性抗菌活性,可抑制细菌叶酸合成、降低大肠菌群数量、抑制肠道细菌生长与维生素生物合成并消耗肠道产叶酸细菌,还可调控肝脏 mTOR 信号通路、减少盲肠发酵、降低肝脏叶酸水平与总叶酸排泄量、提高氮排泄量并降低部分膳食纤维的发酵性,并能在大鼠和 C57BL/6 小鼠中诱导叶酸缺乏,引发生物素和叶酸相关的营养缺乏症状。

生物实验数据

生物活性 Succinylsulfathiazole (Succinylsulphathiazole) is an orally active long-acting sulfonamide antibiotic with gut-localized specific antibacterial activity that inhibits bacterial folate synthesis, reduces colonic bacterial counts, suppresses intestinal bacterial growth and vitamin biosynthesis, and depletes intestinal folate-producing bacteria, while also modulating hepatic mTOR signaling, reducing cecal fermentation, lowering hepatic folate levels and total folate excretion, increasing nitrogen excretion, and decreasing the fermentability of certain dietary fibers, and it can induce folate deficiency and biotin- and folate-related nutritional deficiency symptoms in rats and C57BL/6 mice.
IC50 & Target

mTOR

 

体内研究
(In Vivo)

Succinylsulfathiazole (2%;给药 119 天) 可使 Sunny Hill 品系花斑大鼠的粪便大肠菌群计数出现显著且程度不一的降低,但对需氧菌总数、厌氧菌总数或厌氧孢子计数无显著影响。
Succinylsulfathiazole (2%) 与未添加该药物的常规饲料或纯化饲料相比,可降低 Sunny Hill 花斑大鼠粪便中生物素、叶酸和泛酸的排泄量。
Succinylsulfathiazole (2%;3 天) 可降低 Albino Farms 品系大鼠的粪便大肠菌群数量,而总需氧菌、总厌氧菌或厌氧孢子数量无显著变化。
Succinylsulfathiazole (1%;口服;每日;持续 21 周) 可调控 C57BL/6 小鼠肝脏中 PI3K/AKT/mTOR 信号通路的关键组分及能量代谢调节因子 (在叶酸充足与叶酸缺乏小鼠中对 REDD1 的表达具有差异性作用)。
Succinylsulfathiazole (5 g/kg;口服;自由摄取;27-29 天) 可降低叶酸缺乏的 Sprague-Dawley 大鼠在叶酸补充期间的粪便叶酸排泄量、减少肝脏叶酸储备、降低细菌生长标志物水平,并改变盲肠短链脂肪酸的生成。
Succinylsulfathiazole (2% w/w;口服;持续饲喂;119 天) 可降低粪便大肠菌群数量,减少粪便中生物素和叶酸的排泄,并诱发白细胞减少症。
Succinylsulfathiazole (0.5-2% w/w;口服;持续饲喂) 可降低粪便大肠菌群数量。

Animal Model: C57BL/6 (male, specific pathogen-free, 6 weeks at purchase, studied at 4 months)
Dosage: 1% (incorporated into purified isoenergetic diets, folate adequate: 2 mg folate/kg diet; folate depleted: 0 mg folate/kg diet)
Administration: oral consumption; daily; 21 weeks
Result: Showed no significant difference in body weight gain or food consumption over 21 weeks.
Exhibited no significant differences in folate levels across serum, liver and colon tissues versus untreated controls.
In folate-adequate mice: significantly reduced PDK1 expression and mTORc1 phosphorylation at Ser2448, elevated REDD1 expression, and lowered the ADP/ATP ratio and AMPK phosphorylation.
In folate-depleted mice: significantly decreased REDD1 expression, the ADP/ATP ratio and AMPK phosphorylation.
Reduced 4E-BP1 phosphorylation in both dietary groups.Showed no significant effects on AKT expression, mTORc1 autophosphorylation at Ser2481, S6K1 phosphorylation, autophagy-related proteins (Beclin, ATG5, LC3 cleavage), the NAD+/NADH ratio or SIRT1 expression in either group.
Animal Model: Sprague-Dawley (male weanling, initial weight 45.3 g, folate-depleted by low-folacin AIN93G basal diet for 28 days)
Dosage: 5 g/kg diet
Administration: oral; ad libitum; 27-29 days
Result: Reduced total folate excretion from 13.8 to 4.8 nmol/d (pooled diets).
Lowered mean liver folate concentration from 11.6 to 7.5 nmol/g (pooled diets); this reduction was significant in rats fed standard, ground corn, wheat germ, inulin and polydextrose diets, but not in those fed wheat bran or oat bran diets.
Decreased diaminopimelic acid and muramic acid excretion, and increased nitrogen excretion (pooled diets).
Reduced fermentability of oat bran, ground corn, and wheat germ fibers; had no effect on wheat bran fiber, inulin, or polydextrose fermentability.
Lowered cecal acetic acid and propionic acid contents overall, with a diet×antibiotic interaction for propionic acid.
Animal Model: Sunny Hill strain piebald rats (~75 days old when placed on succinylsulfathiazole diet)
Dosage: 2% w/w
Administration: oral; continuous feeding; 119 days
Result: Dropped fecal coliform counts immediately, with one rat averaging 105 per gram feces, another averaging 103 per gram feces with wide fluctuation (0-108), and the third having feces almost entirely devoid of coliforms until near the end of the experiment when counts rose to 104 per gram.
Showed no significant change in total aerobic and anaerobic organism counts, and anaerobic spore counts compared to pre-drug diet levels.
Reduced fecal excretion of biotin to 0.28 μg/gm feces and 0.39 μg/day, and folic acid to 2.5 μg/gm feces and 4.2 μg/day, significantly lower than in rats fed stock or purified diets without succinylsulfathiazole.
Induced low total leucocyte counts prior to vitamin supplementation.
Animal Model: Albino Farms strain rats (~60 days old when placed on succinylsulfathiazole diet)
Dosage: 0.5% w/w; 2% w/w
Administration: oral; continuous feeding
Result: Reduced fecal coliform counts to a low level with 2% w/w diet, though this reduction occurred more slowly than with an equivalent level of phthalylsulfathiazole.
Resulted in fecal coliform counts < 104 per gram feces after 3 days of feeding with 0.5% w/w diet.
Showed no significant change in total aerobic and anaerobic organism counts, and anaerobic spore counts compared to pre-drug diet levels.
性状 固体
颜色 White to off-white

化学信息

分子量 355.39
分子式 C13H13N3O5S2
CAS No. 116-43-8
别名 琥珀酰磺胺噻唑; Succinylsulphathiazole

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.00 mg/mL (5.63 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (281.38 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 1 mg/mL (2.81 mM; 超声助溶 (<80°C))

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM2.8138 mL14.0691 mL28.1381 mL70.3453 mL
DMSO5 mM0.5628 mL2.8138 mL5.6276 mL14.0691 mL
10 mM0.2814 mL1.4069 mL2.8138 mL7.0345 mL
15 mM0.1876 mL0.9379 mL1.8759 mL4.6897 mL
20 mM0.1407 mL0.7035 mL1.4069 mL3.5173 mL
25 mM0.1126 mL0.5628 mL1.1255 mL2.8138 mL
30 mM0.0938 mL0.4690 mL0.9379 mL2.3448 mL
40 mM0.0703 mL0.3517 mL0.7035 mL1.7586 mL
50 mM0.0563 mL0.2814 mL0.5628 mL1.4069 mL
60 mM0.0469 mL0.2345 mL0.4690 mL1.1724 mL
80 mM0.0352 mL0.1759 mL0.3517 mL0.8793 mL
100 mM0.0281 mL0.1407 mL0.2814 mL0.7035 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础